Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMT2.93
- Development stage
- Preclinical
- Lead developer
- Universidad Pablo de Olavide
- Modality
- Small Molecules
01
Overview
MMT2.93 is a thiophene derivative small molecule antimicrobial candidate under preclinical development for the treatment of multidrug-resistant (MDR) Gram-negative bacterial infections, specifically those caused by *Acinetobacter baumannii* and *Escherichia coli*. Developed by the Universidad Pablo de Olavide and the Spanish National Research Council (CSIC), MMT2.93 targets bacterial outer membrane proteins (OMPs), specifically Omp33 in *A. baumannii* and OmpC in *E. coli*. Binding to these targets disrupts cell wall and membrane integrity, leading to structural changes similar to those caused by membrane-targeting antibiotics. MMT2.93 exhibits low in vivo toxicity and demonstrates significant synergistic bactericidal activity when combined with colistin, effectively restoring colistin sensitivity in resistant strains.
- Other names
- MMT 2.93MMT2.93MMT-2.93
02
Targets
Omp33-36 (33-36 kDa outer membrane protein)OmpC (Outer membrane porin C)
Beyond the preview
Go deeper on MMT2.93.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMT2.93.